Akorn Inc divests ECR Pharmaceuticals to Valeant


Friday, 20 Jun 2014 11:11am EDT 

Akorn Inc:Says it sold its subsidiary, ECR Pharmaceuticals (ECR), to Valeant Pharmaceuticals for $41 mln in cash and assumption of certain liabilities.ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal.